Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma

Table 4 Comparative analysis of coagulation biomarker responses between the two groups, mean ± SD

	Experimental group (n = 45)	Control group (n = 44)	F value	P value
APTT, second			3.105	0.082
Before treatment	36.52 ± 3.06	37.45 ± 3.34	0.024	0.878
3 months after treatment	31.27 ± 2.94	32.42 ± 3.15
D-D, μg/mL			0.686	0.105
Before treatment	1.68 ± 0.37	1.75 ± 0.33	0.048	0.826
3 months after treatment	1.51 ± 0.35	1.62 ± 0.25
Fbg, g/L			28.943	< 0.001
Before treatment	2.06 ± 0.56	1.89 ± 0.52	0.167	0.684
3 months after treatment	2.87 ± 0.59	2.15 ± 0.68
PT, second			14.511	< 0.001
Before treatment	12.26 ± 2.18	11.97 ± 2.42	1.250	0.267
3 months after treatment	9.25 ± 2.13	10.92 ± 2.10
TT, second			19.431	< 0.001
Before treatment	16.72 ± 2.08	16.53 ± 2.26	1.910	0.170
3 months after treatment	13.25 ± 2.17	15.42 ± 2.42

APTT: Activated partial thromboplastin time; D-D: D-dimer; Fbg: Fibrinogen; PT: Prothrombin time; TT: Thrombin time.